WALTHAM, Mass. – Thermo Fisher Scientific has announced plans to acquire Sanofi’s sterile manufacturing site in Ridgefield, New Jersey, as part of an expanded partnership between the two companies aimed at boosting U.S. drug production capabilities. Terms of the deal were not disclosed.
The Ridgefield site, a modern fill-finish and packaging facility employing more than 200 people, will continue to produce a portfolio of therapies for Sanofi after the transition. Thermo Fisher also plans to expand the site’s use to accommodate growing demand from pharmaceutical and biotech clients for U.S.-based manufacturing.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president and CEO of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
Brendan O’Callaghan, Sanofi’s global head of manufacturing & supply, emphasized the strategic value of the deal for both companies.
“This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site,” O’Callaghan said.
Thermo Fisher already operates U.S. sterile fill-finish facilities in Greenville, North Carolina, and Plainville, Massachusetts. These sites form part of the company’s Accelerator™ Drug Development platform, offering contract development and manufacturing (CDMO) and contract research (CRO) services designed to help emerging biotech and biopharma companies bring medicines to market faster.
The Ridgefield acquisition is expected to close in the second half of 2025, pending customary regulatory approvals. Once finalized, the facility will become part of Thermo Fisher’s pharma services business under its Laboratory Products and Biopharma Services segment.
